Patent number 11345886 was issued on May 31, 2022. This is the fourth patent for SMSbiotech and our platform technology.
We currently have nine additional patents pending approval. The patents cover the composition, methods, and uses of both Small Mobile Stem (SMS) cell therapy and ECM product applications.
Many thanks to Knobbe Martens, one of the largest US IP and technology law firms, for their IP strategy on SMSbiotech technology.